Comparative Pharmacology
Head-to-head clinical analysis: TEMAZEPAM versus ZAXOPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEMAZEPAM versus ZAXOPAM.
TEMAZEPAM vs ZAXOPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the effect of GABA by increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
Zaxopam is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion influx and causing neuronal hyperpolarization.
10-20 mg orally at bedtime, up to 30 mg in severe insomnia.
10 mg orally twice daily, titrated to a maximum of 30 mg twice daily based on response and tolerability; oral route.
None Documented
None Documented
Terminal elimination half-life is 8–20 hours in healthy adults (mean ~15 hours); may be prolonged in elderly (up to 50 hours) and in hepatic impairment (up to 40 hours); clinical context: typical dosing interval is 12–24 hours.
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderateTemazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."
Clinical Note
moderateTemazepam + Sulfisoxazole
Terminal elimination half-life is 12-15 hours, allowing for once-daily dosing in most patients.
Renal excretion of conjugated metabolites (primarily as glucuronide) accounts for approximately 80% of an oral dose; fecal excretion accounts for about 12%; less than 1% is excreted unchanged in urine.
Renal excretion accounts for approximately 80% of the administered dose, predominantly as conjugated metabolites; biliary/fecal excretion accounts for the remaining 20%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Temazepam."